Article Information
History
- January 18, 2022.
Copyright
The copyright holder for this preprint is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a CC-BY-NC-ND 4.0 International license.
Author Information
- Alexandra B Hogan1,*,
- Sean L Wu2,
- Patrick Doohan1,
- Oliver J Watson1,3,
- Peter Winskill1,
- Giovanni Charles1,
- Gregory Barnsley1,
- Eleanor M Riley4,
- David S Khoury5,
- Neil M Ferguson1 and
- Azra C Ghani1,*
- 1MRC Centre for Global Infectious Disease Analysis, Jameel Institute, School of Public Health, Imperial College London, London, UK
- 2Institute for Health Metrics and Evaluation, University of Washington, Seattle, USA
- 3London School of Hygiene and Tropical Medicine, London, UK
- 4Institute of Immunology and Infection Research, School of Biological Sciences, University of Edinburgh, UK
- 5Kirby Institute, University of New South Wales, Sydney, Australia
- ↵*Correspondence: Dr Alexandra Hogan (a.hogan{at}imperial.ac.uk), Professor Azra Ghani (a.ghani{at}imperial.ac.uk)
Posted January 18, 2022.
The value of vaccine booster doses to mitigate the global impact of the Omicron SARS-CoV-2 variant
